Google
Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint
Neuphoria Therapeutics (NEUP) said Monday that a phase 3 trial of BNC210 for the acute treatment of
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
